Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Author(s): Haiyan Bao, Depei Wu. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006,, China
Journal Name: Current Stem Cell Research & Therapy
DOI : 10.2174/1574888X11666161226150159
With the development of chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis of leukemia patients has been improved greatly in the past few decades. However, relapsed and refractory leukemia is still the major cause of mortality in leukemia patients. Besides, advancing age, poor performance status and severe co-morbidities limit the applicability of cytotoxic chemotherapy in certain groups of leukemia patients. Novel agents including nucleoside analogs, kinase inhibitors targeting oncoproteins and monoclonal antibodies are under investigation for the management of leukemia. Nevertheless, the outcome remains disappointing. Since immune system plays an important role in eradicating tumor cells, a lot of studies have been conducted in the administration of cytotherapy of immune cells as an alternative method when chemotherapy and transplantation fail to cure the disease, including usage of natural killer (NK) cells, cytokine-induced killer (CIK) cells, donor lymphocyte infusion (DLI), chimeric antigen receptor (CAR)-modified T cells, dendritic cell (DC)-based vaccine and antigen-specific cytotoxic T lymphocytes (CTL). Due to overexpression of several leukemia associated antigens (LAA), leukemic cells are potentially suitable for cellular therapy approach. Here we review the recent literature regarding the different types of cytotherapy against leukemia, and talk about both efficacy and adverse effects related to the strategy.
Keywords: Leukemia, cytotherapy, natural killer cells, cytokine-induced killer cells, donor lymphocyte infusion, chimeric antigen receptor, dendritic cells.
Current Stem Cell Research & Therapy
Title:Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Author(s):Haiyan Bao and Depei Wu
Affiliation:Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 215006
Keywords:Leukemia, cytotherapy, natural killer cells, cytokine-induced killer cells, donor lymphocyte infusion, chimeric antigen receptor, dendritic cells.
Abstract:With the development of chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis of leukemia patients has been improved greatly in the past few decades. However, relapsed and refractory leukemia is still the major cause of mortality in leukemia patients. Besides, advancing age, poor performance status and severe co-morbidities limit the applicability of cytotoxic chemotherapy in certain groups of leukemia patients. Novel agents including nucleoside analogs, kinase inhibitors targeting oncoproteins and monoclonal antibodies are under investigation for the management of leukemia. Nevertheless, the outcome remains disappointing. Since immune system plays an important role in eradicating tumor cells, a lot of studies have been conducted in the administration of cytotherapy of immune cells as an alternative method when chemotherapy and transplantation fail to cure the disease, including usage of natural killer (NK) cells, cytokine-induced killer (CIK) cells, donor lymphocyte infusion (DLI), chimeric antigen receptor (CAR)-modified T cells, dendritic cell (DC)-based vaccine and antigen-specific cytotoxic T lymphocytes (CTL). Due to overexpression of several leukemia associated antigens (LAA), leukemic cells are potentially suitable for cellular therapy approach. Here we review the recent literature regarding the different types of cytotherapy against leukemia, and talk about both efficacy and adverse effects related to the strategy.
Haiyan Bao and Depei Wu, "Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells", Current Stem Cell Research & Therapy (2017) 12: 188. https://doi.org/10.2174/1574888X11666161226150159
https://doi.org/10.2174/1574888X11666161226150159 Print ISSN
DOI: 10.2174/1574888X11666161226150159
Related Article(s)
The Interaction of Fungi with Dendritic Cells: Implications for Th Immunity and Vaccination
Current Molecular Medicine
Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents
Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Anti-inflammatory and Antioxidant Activities of the Extracts from Leaves and Stems of Polygonum odoratum Lour
Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry
Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews
Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Targeting the Chemokines in Cardiac Repair
Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery
Hair Regeneration Therapy: Application of Adipose-Derived Stem Cells
Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews
Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research
A Review of HPLC Methods Used for Determining the Presence of Meloxicam
Current Pharmaceutical Analysis
Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders
Current Drug Targets - Infectious Disorders
Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology
Under Performance of Anti Tuberculosis Vaccine MVA85A in BCGPrimed Subjects: A Commentary
Current Immunology Reviews